Loading...
•
Sep 30, 2022
Ironwood Pharmaceuticals Q3 2022 Earnings Report
Reported strong performance driven by LINZESS, exceeding 1 million total prescriptions in a quarter.
Key Takeaways
Ironwood Pharmaceuticals reported strong Q3 2022 results, with LINZESS exceeding 1 million total prescriptions in a quarter and a 10% year-over-year increase in EUTRx prescription demand. GAAP net income was $50 million, and adjusted EBITDA was $69 million, with $574 million in cash and cash equivalents at the end of the quarter. The company maintains its full-year 2022 financial guidance.
LINZESS EUTRx prescription demand growth increased 10% year-over-year.
LINZESS exceeded 1 million total prescriptions in a quarter.
GAAP net income of $50 million and adjusted EBITDA of $69 million were reported.
Ended Q3 2022 with $574 million in cash and cash equivalents.
Forward Guidance
Ironwood Pharmaceuticals maintains its full year 2022 financial guidance.
Positive Outlook
- U.S. LINZESS net sales growth of low single digits %
- Total Ironwood revenue of $420 to $430 million
- Adjusted EBITDA of >$250 million
- Continued focused investments
- Commitment to reaching new patients to drive prescription demand growth moving forward
Challenges Ahead
- Unable to predict with reasonable certainty the non-GAAP adjustments used to calculate adjusted EBITDA.
- Adjustments are uncertain
- Depend on various factors
- Could have a material impact on GAAP net income for the guidance period.
- May not incur material expenses related to business development activities in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...